Prednisone in Cystic Fibrosis Pulmonary Exacerbations

Exclusion Criteria

• •1. A respiratory tract culture positive for Burkholderia cenocepacia in the 12 months prior to enrollment
• •2. A respiratory tract culture positive for Mycobacterium abscessus in the 12 months prior to enrollment
• •3. Treatment with IV or oral corticosteroids within 2 weeks of enrollment or from Day 0-Day 7 of the pulmonary exacerbation
• •4. Active allergic bronchopulmonary aspergillosis (ABPA) at the time of enrollment as determined by treating physician
• •5. Asthma related exacerbation at enrollment as defined by the treating physician based on clinically compatible symptoms (eg. wheeze)
• •6. History of avascular necrosis or pathologic bone fracture
• •7. Uncontrolled hypertension with end organ damage
• •8. Active gastrointestinal bleeding
• •9. Status post lung or other organ transplantation
• •10. Pregnancy
• •11. Lactose intolerance (contained in placebo)
• •12. On Lumacaftor-Ivacaftor (Orkambi) at the time of exacerbation
• •13. Investigational drug use within 30 days prior to enrollment visit
• •14. Physical findings that would compromise the safety of the subject or the quality of the study data as determined by site investigator